Women's health sector faces massive growth potential amid systemic funding gaps

Global reports highlight a significant shift and massive economic potential in the women's health sector. A Deloitte analysis projects that additional spending on women's health could reach $527 billion by 2030, driven by an aging population in the U.S. and a growing recognition of sex-specific biological needs. The report suggests that increased investment and earlier interventions could extend women's healthspan by up to 20 years.

However, systemic gaps remain. Data from the World Economic Forum reveals a mismatch between disease burden and research funding. While conditions like ischemic heart disease and osteoarthritis disproportionately affect women, they receive minimal dedicated funding—often less than 6% and 2% respectively. Currently, over 59% of women-specific research funds are concentrated in ovarian cancer and menopause, creating a “head concentration effect” that leaves other high-burden areas underserved.

Geographic and structural imbalances also persist. More than 80% of global women's health research funding is concentrated in North America, with the National Institutes of Health (NIH) providing the vast majority of that support. This leaves significant innovation gaps in Europe, Asia, Africa, and Latin America. Experts suggest that closing these gaps requires moving beyond market mechanisms to integrate clinical evidence, regulatory support, and targeted capital to address the full spectrum of women's health, including mental health and chronic disease management.